Mutual of America Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $725K | Buy |
2,295
+43
| +2% | +$10.1K | 0.01% | 1056 |
|
|
2026
Q1 | $450K | Buy |
2,252
+2
| +0.1% | +$396 | 0.01% | 1086 |
|
|
2025
Q4 | $425K | Buy |
2,250
+55
| +3% | +$10.6K | ﹤0.01% | 1102 |
|
|
2025
Q3 | $389K | Sell |
2,195
-284
| -11% | -$42.2K | ﹤0.01% | 1122 |
|
|
2025
Q2 | $282K | Sell |
2,479
-273
| -10% | -$29.2K | ﹤0.01% | 1224 |
|
|
2025
Q1 | $289K | Sell |
2,752
-110
| -4% | -$12.4K | ﹤0.01% | 1247 |
|
|
2024
Q4 | $307K | Buy |
2,862
+115
| +4% | +$13K | ﹤0.01% | 1273 |
|
|
2024
Q3 | $275K | Sell |
2,747
-29
| -1% | -$2.92K | ﹤0.01% | 1312 |
|
|
2024
Q2 | $234K | Sell |
2,776
-48
| -2% | -$3.82K | ﹤0.01% | 1358 |
|
|
2024
Q1 | $206K | Sell |
2,824
-45
| -2% | -$3.32K | ﹤0.01% | 1409 |
|
|
2023
Q4 | $205K | Buy |
+2,869
| New | +$169K | ﹤0.01% | 1407 |
|
|
2023
Q3 | – | Sell |
-3,206
| Closed | -$231K | – | 1467 |
|
|
2023
Q2 | $231K | Sell |
3,206
-98
| -3% | -$7.35K | ﹤0.01% | 1369 |
|
|
2023
Q1 | $243K | Sell |
3,304
-60
| -2% | -$4.26K | ﹤0.01% | 1340 |
|
|
2022
Q4 | $225K | Sell |
3,364
-1,751
| -34% | -$114K | ﹤0.01% | 1362 |
|
|
2022
Q3 | $275K | Buy |
5,115
+575
| +13% | +$33.8K | ﹤0.01% | 1263 |
|
|
2022
Q2 | $253K | Buy |
4,540
+682
| +18% | +$38.7K | ﹤0.01% | 1252 |
|
|
2022
Q1 | $271K | Buy |
3,858
+197
| +5% | +$14.3K | ﹤0.01% | 1253 |
|
|
2021
Q4 | $353K | Buy |
3,661
+96
| +3% | +$8.87K | ﹤0.01% | 1195 |
|
|
2021
Q3 | $310K | Sell |
3,565
-19,900
| -85% | -$1.54M | ﹤0.01% | 1217 |
|
|
2021
Q2 | $1.92M | Sell |
23,465
-319
| -1% | -$26.5K | 0.02% | 982 |
|
|
2021
Q1 | $2.26M | Sell |
23,784
-540
| -2% | -$51K | 0.02% | 912 |
|
|
2020
Q4 | $1.51M | Buy |
24,324
+90
| +0.4% | +$5.13K | 0.02% | 999 |
|
|
2020
Q3 | $1.44M | Buy |
24,234
+319
| +1% | +$21.8K | 0.02% | 952 |
|
|
2020
Q2 | $1.67M | Sell |
23,915
-661
| -3% | -$41.9K | 0.02% | 901 |
|
|
2020
Q1 | $1.11M | Sell |
24,576
-1,255
| -5% | -$71.1K | 0.02% | 950 |
|
|
2019
Q4 | $1.68M | Sell |
25,831
-1,399
| -5% | -$93.5K | 0.02% | 979 |
|
|
2019
Q3 | $1.69M | Sell |
27,230
-564
| -2% | -$35.4K | 0.02% | 926 |
|
|
2019
Q2 | $1.98M | Sell |
27,794
-1,010
| -4% | -$74.4K | 0.03% | 880 |
|
|
2019
Q1 | $2.26M | Sell |
28,804
-1,331
| -4% | -$101K | 0.03% | 815 |
|
|
2018
Q4 | $2.55M | Buy |
30,135
+29,492
| +4,587% | +$3.14M | 0.04% | 677 |
|
|
2018
Q3 | $110K | Buy |
643
+518
| +414% | +$78.1K | ﹤0.01% | 1171 |
|
|
2018
Q2 | $16K | Buy |
+125
| New | +$13.9K | ﹤0.01% | 1216 |
|
|
2014
Q3 | – | Sell |
-641
| Closed | -$25K | – | 1262 |
|
|
2014
Q2 | $25K | Buy |
+641
| New | +$26K | ﹤0.01% | 1247 |
|
Other funds holding LGND
JT
CAM
Mutual of America Capital Management's LGND Position: Q2 2026 in Review
Mutual of America Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 1.9% in Q2 2026, buying an estimated $10.1K and bringing the position to 2,295 shares worth $725K. The position accounts for 0.01% of the portfolio, ranked #1056.
Mutual of America Capital Management first reported a position in LGND in Q2 2014 and has held it in 33 quarters since. The position peaked at $2.55M in Q4 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Mutual of America Capital Management held 2,295 shares of Ligand Pharmaceuticals worth $725K as of Q2 2026.
- Mutual of America Capital Management bought 43 Ligand Pharmaceuticals shares in Q2 2026, an estimated $10.1K.
- Ligand Pharmaceuticals made up 0.01% of Mutual of America Capital Management's portfolio in Q2 2026, its #1056 holding.
- Mutual of America Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and has held it in 33 quarters since.
- Mutual of America Capital Management's Ligand Pharmaceuticals position peaked at $2.55M in Q4 2018.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.